Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease - PubMed (original) (raw)

Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease

Ning Song et al. Free Radic Biol Med. 2010.

Abstract

Iron-induced oxidative stress is thought to play a crucial role in the pathogenesis of Parkinson's disease (PD). Based on our previous in vivo experiments showing that down-regulation of the iron transporters ferroportin 1 (FP1) and hephaestin (HP) might account for the nigral iron accumulation in 6-hydroxydopamine (6-OHDA)-lesioned animal models, in this study we investigated whether FP1 and HP were involved in cellular iron accumulation and the underlying mechanisms in a cell model of PD. The findings showed that 6-OHDA induced FP1 and HP down-regulation, followed by decreased iron efflux and iron accumulation in primary ventral mesencephalic neurons and MES23.5 dopaminergic cells. Silencing of FP1 but not HP led to increased iron levels and aggravated reactive oxygen species generation in MES23.5 cells. Under iron-overloaded conditions, FP1 showed dose-dependent up-regulation, whereas HP showed no response, indicating their down-regulation was not due to the increased intracellular iron content. In 6-OHDA-treated cells, both iron-regulatory protein (IRP) 1 and IRP2 were up-regulated, and silencing of IRPs in MES23.5 cells dramatically blocked 6-OHDA-induced FP1 down-regulation and reversed HP down-regulation. These results suggest that FP1 but not HP contributes to 6-OHDA-induced intracellular iron accumulation, and down-regulation of FP1 and HP by 6-OHDA is IRPs-dependent.

PubMed Disclaimer

Cited by

Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies.
Ma L, Gholam Azad M, Dharmasivam M, Richardson V, Quinn RJ, Feng Y, Pountney DL, Tonissen KF, Mellick GD, Yanatori I, Richardson DR. Ma L, et al. Redox Biol. 2021 May;41:101896. doi: 10.1016/j.redox.2021.101896. Epub 2021 Feb 14. Redox Biol. 2021. PMID: 33799121 Free PMC article. Review.
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences.
Koziorowski D, Figura M, Milanowski ŁM, Szlufik S, Alster P, Madetko N, Friedman A. Koziorowski D, et al. Cells. 2021 Mar 16;10(3):656. doi: 10.3390/cells10030656. Cells. 2021. PMID: 33809527 Free PMC article. Review.
New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.
Xu H, Jiang H, Xie J. Xu H, et al. Front Mol Neurosci. 2017 Mar 16;10:71. doi: 10.3389/fnmol.2017.00071. eCollection 2017. Front Mol Neurosci. 2017. PMID: 28360837 Free PMC article. Review.
Study of molecular patterns associated with ferroptosis in Parkinson's disease and its immune signature.
Chen L, Xin G, He Y, Tian Q, Kong X, Fu Y, Wang J, Zhang H, Wang L. Chen L, et al. PLoS One. 2023 Dec 21;18(12):e0295699. doi: 10.1371/journal.pone.0295699. eCollection 2023. PLoS One. 2023. PMID: 38127902 Free PMC article.
Overdosing on iron: Elevated iron and degenerative brain disorders.
D'Mello SR, Kindy MC. D'Mello SR, et al. Exp Biol Med (Maywood). 2020 Oct;245(16):1444-1473. doi: 10.1177/1535370220953065. Epub 2020 Sep 2. Exp Biol Med (Maywood). 2020. PMID: 32878460 Free PMC article. Review.

Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease - PubMed (original) (raw)